Press Releases
25-09-2023, 23:17 CEST (Ad hoc press release)
Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
13-09-2023
Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
21-07-2023, 15:21 CEST (Ad hoc press release)
Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
08-06-2023
Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
07-06-2023
ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.
08-05-2023
Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
25-04-2023, 17:59 CEST (Ad hoc press release)
Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
24-03-2023
Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
01-02-2023
Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
